These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Azimilide dihydrochloride: a unique class III antiarrhythmic agent. Tran HT Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612 [TBL] [Abstract][Full Text] [Related]
24. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444 [TBL] [Abstract][Full Text] [Related]
25. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. Singh S J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742 [TBL] [Abstract][Full Text] [Related]
26. Oral class III antiarrhythmics: what is new? Khan MH Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634 [TBL] [Abstract][Full Text] [Related]
27. [Current strategies of pharmacological and non-pharmacological treatment in atrial fibrillation and atrial flutter]. Kobayashi Y Nihon Rinsho; 2002 Jul; 60(7):1373-81. PubMed ID: 12136617 [TBL] [Abstract][Full Text] [Related]
30. Current management of symptomatic atrial fibrillation. Haghi D; Schumacher B Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042 [TBL] [Abstract][Full Text] [Related]
31. Azimilide dihydrochloride, a novel antiarrhythmic agent. Karam R; Marcello S; Brooks RR; Corey AE; Moore A Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222 [TBL] [Abstract][Full Text] [Related]
32. [Antiarrhythmic therapy in patients with heart failure]. Faber TS; Zehender M Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [TBL] [Abstract][Full Text] [Related]
33. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE; Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacological therapy of atrial fibrillation and atrial flutter]. Grönefeld GC; Li YG; Hohnloser SH Herz; 2002 Jun; 27(4):329-44. PubMed ID: 12187863 [TBL] [Abstract][Full Text] [Related]
35. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
36. Clinical differences between the newer antiarrhythmic agents. Camm AJ Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520 [TBL] [Abstract][Full Text] [Related]
37. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods. Naegeli B; Straumann E; Bertel O Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188 [TBL] [Abstract][Full Text] [Related]
38. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Van Gelder IC; Tuinenburg AE; Schoonderwoerd BS; Tieleman RG; Crijns HJ Am J Cardiol; 1999 Nov; 84(9A):147R-151R. PubMed ID: 10568674 [TBL] [Abstract][Full Text] [Related]
39. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Singh BN Heart Fail Rev; 2002 Jul; 7(3):285-300. PubMed ID: 12215733 [TBL] [Abstract][Full Text] [Related]
40. Differential atrial versus ventricular activities of class III potassium channel blockers. Baskin EP; Lynch JJ J Pharmacol Exp Ther; 1998 Apr; 285(1):135-42. PubMed ID: 9536003 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]